This trial is active, not recruiting.

Condition chronic idiopathic constipation
Treatments ykp10811, placebo
Phase phase 2
Sponsor SK Life Science
Start date October 2013
End date May 2015
Trial size 320 participants
Trial identifier NCT01989234, YKP10811C006


This will be a multi-center, randomized, double-blind, placebo-controlled study of YKP10811 capsules in patients with chronic idiopathic constipation. Following a 2-week baseline period, approximately 320 eligible patients with <3 complete spontaneous bowel movements (CSBM) and ≤ 5 SBMs per week will be randomly assigned equally to receive one of the following oral treatments; placebo or YKP10811 capsules once daily for 12 weeks followed by a 2 week follow-up period.

The objectives of this study are:

- To assess the efficacy of YKP10811 once daily at relieving constipation and associated symptoms in subjects with chronic idiopathic constipation.

- To determine the safety and tolerability of YKP10811 once daily in subjects with chronic idiopathic constipation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
(Placebo Comparator)
Placebo Comparator
YKP10811 High Dose
YKP10811 Mid Dose
YKP10811 Low Dose

Primary Outcomes

The proportion of subjects with improved bowel movement frequency
time frame: 12 weeks

Secondary Outcomes

Stool frequency
time frame: 12 weeks
Daily average ratings of stool consistency
time frame: 12 weeks
Instances of rescue medicine usage
time frame: 12 weeks
Onset time to CSBM
time frame: 12 weeks
Onset time to SBM
time frame: 12 weeks
Severity of straining
time frame: 12 weeks
Abdominal discomfort
time frame: 12 weeks
Abdominal pain
time frame: 12 weeks
time frame: 12 weeks
Constipation severity
time frame: 12 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Patients who meet modified Rome II criteria for Chronic Constipation. - Patients who are male or female, 18 to 65 years of age inclusive. - At Visit 3, patients must have < 3 CSBMs per week and ≤ 5 SBMs per week during the 2-week baseline period. Exclusion Criteria: - Patients who meet Rome II criteria for Irritable Bowel Syndrome (IBS-C). - Patients with constipation that is drug-induced, or secondary to endocrine, metabolic or, surgery. - Patients with a clinically significant diseases that would limit the patient's ability to complete and/or participate in the study, including gastrointestinal disorder or surgery, an endocrine abnormality (e.g., diabetes), impaired renal function (GFR of < 55mL/minute/1.73m2), uncontrolled pulmonary diseases (including asthma), uncontrolled cardiovascular disease (a history of myocardial infarction or cerebrovascular accident within 6 months prior to screening) or significant neurological diseases. - Patients with a history of inflammatory bowel disease. - Patients with a history of cancer (other than basal cell or squamous cell carcinoma of the skin completely excised) unless the malignancy has been in complete remission for at least 5 years prior to screening. - Patients who started a special diet and/or an intense physical workout program within 30 days prior to the beginning of the baseline period or who are intending to substantially modify their dietary habits at any time during the study (patients on a stable, continuous regimen of fiber therapy for at least 30 days prior to the pretreatment baseline period are allowed to continue that therapy, provided that they continue at a constant dose throughout the study. - Patients with a history of clinically significant hypersensitivity or allergy (facial swelling, hives, breathing difficulty, Stevens-Johnson syndrome etc), in response to any medication, either prescription or nonprescription including an investigational drug, dietary supplement, or herbal medicine.

Trial information was received from ClinicalTrials.gov and was last updated in June 2014.
Information provided to ClinicalTrials.gov by SK Life Science.